La traduzione di questa pagina è sperimentale e in fase di sviluppo. Siamo lieti di ricevere vostro !

PharmaCielo Gestione

Gestione criteri di controllo 2/4

PharmaCielo's Il CEO è Marc Lustig, nominato in Jul2023, ha un mandato di 1.08 anni. possiede direttamente 3.15% delle azioni della società, per un valore di CA$ 587.54K. La durata media del mandato del team dirigenziale e del consiglio di amministrazione è rispettivamente 2.1 anni e 5.3 anni.

Informazioni chiave

Marc Lustig

Amministratore delegato

n/a

Compenso totale

Percentuale dello stipendio del CEO	n/a
Mandato del CEO	1.1yrs
Proprietà del CEO	3.1%
Durata media del management	2.1yrs
Durata media del Consiglio di amministrazione	5.3yrs

Aggiornamenti recenti sulla gestione

Recent updates

AMMINISTRATORE DELEGATO

Marc Lustig (50 yo)

1.1yrs

Mandato

CA$57,500

Compensazione

Mr. Marc Lustig, M. Sc., M. B.A., had been an Executive Chairman at IM Cannabis Corp. since December 29, 2020 and had been its Director since October 11, 2019 until June 05, 2024. He has been Chairman and...

Gruppo dirigente

Nome	Posizione	Mandato	Compensazione	Proprietà
Marc Lustig	Chairman & CEO	1.1yrs	CA$57.50k	3.15% CA$ 587.5k
Ian Atacan	CFO, Corporate Secretary & Director	3.2yrs	CA$275.00k	0.32% CA$ 60.0k
Andres Botero	Chief Operating Officer	no data	CA$290.57k	Nessun dato
Decio de Castro Filho	Chief Medical Officer	2.1yrs	Nessun dato	Nessun dato

2.1yrs

Durata media

Gestione esperta: Il team dirigenziale di PCLO è considerato esperto (durata media dell'incarico 2.1 anni).

Membri del Consiglio di amministrazione

Nome	Posizione	Mandato	Compensazione	Proprietà
Marc Lustig	Chairman & CEO	3.8yrs	CA$57.50k	3.15% CA$ 587.5k
Ian Atacan	CFO, Corporate Secretary & Director	2.1yrs	CA$275.00k	0.32% CA$ 60.0k
Anders Milton	Member of Medical & Scientific Advisory Board	7.8yrs	Nessun dato	Nessun dato
Douglas Bache	Independent Director	5.6yrs	CA$60.00k	0.041% CA$ 7.7k
Riccardo Polosa	Member of Medical & Scientific Advisory Board	5.3yrs	Nessun dato	Nessun dato
Nadia Crosignani	Member of Medical & Scientific Advisory Board	5.3yrs	Nessun dato	Nessun dato
Konstantinos Farsalinos	Member of Medical & Scientific Advisory Board	5.3yrs	Nessun dato	Nessun dato
Gerard Madlambayan	Member of Medical & Scientific Advisory Board	5.3yrs	Nessun dato	Nessun dato
Solomon Rataemane	Member of Medical & Scientific Advisory Board	5.3yrs	Nessun dato	Nessun dato
David Richardson	Member of Medical & Scientific Advisory Board	5.3yrs	Nessun dato	Nessun dato
William Petron	Lead Independent Director	3.2yrs	CA$541.68k	2.37% CA$ 442.2k

5.3yrs

Durata media

Consiglio di amministrazione esperto: I membri del consiglio di amministrazione di PCLO sono considerati esperti (durata media dell'incarico 5.3 anni).

PharmaCielo Gestione

Gestione criteri di controllo 2/4

Informazioni chiave

Aggiornamenti recenti sulla gestione

PharmaCielo Ltd., Annual General Meeting, Feb 20, 2024

Pharmacielo Ltd. Appoints Marc Lustig as CEO

CEO, President & Chairman of the Board exercised options to buy CA$33k worth of stock.

Independent Lead Director recently bought CA$83k worth of stock

Less than half of directors are independent

Less than half of directors are independent

Recent updates

Second quarter 2024 earnings released: CA$0.015 loss per share (vs CA$0.023 loss in 2Q 2023)

PharmaCielo Ltd. announced that it expects to receive CAD 2 million in funding

PharmaCielo Ltd. announced that it expects to receive CAD 2 million in funding

PharmaCielo Ltd., Annual General Meeting, Feb 20, 2024

Third quarter 2023 earnings released: CA$0.017 loss per share (vs CA$0.034 loss in 3Q 2022)

PharmaCielo Ltd. announced that it has received CAD 4.78 million in funding

Is PharmaCielo (CVE:PCLO) Using Too Much Debt?

New major risk - Financial position

Second quarter 2023 earnings released: CA$0.023 loss per share (vs CA$0.023 loss in 2Q 2022)

Pharmacielo Ltd. Appoints Marc Lustig as CEO

PharmaCielo Ltd. announced that it expects to receive CAD 5 million in funding

CEO, President & Chairman of the Board exercised options to buy CA$33k worth of stock.

New minor risk - Share price stability

First quarter 2023 earnings released: CA$0.023 loss per share (vs CA$0.019 loss in 1Q 2022)

Full year 2022 earnings released: CA$0.096 loss per share (vs CA$0.18 loss in FY 2021)

Is PharmaCielo (CVE:PCLO) Using Too Much Debt?

Independent Lead Director recently bought CA$83k worth of stock

Less than half of directors are independent

Third quarter 2022 earnings released: CA$0.034 loss per share (vs CA$0.059 loss in 3Q 2021)

Second quarter 2022 earnings released: CA$0.023 loss per share (vs CA$0.049 loss in 2Q 2021)

PharmaCielo (CVE:PCLO) Is Making Moderate Use Of Debt

Less than half of directors are independent

PharmaCielo Ltd. Announces Board and Executive Changes

CEO, President & Chairman of the Board recently bought CA$67k worth of stock

PharmaCielo Ltd., Annual General Meeting, Sep 01, 2022

CEO, President & Chairman of the Board exercised options to buy CA$87k worth of stock.

First quarter 2022 earnings: EPS and revenues miss analyst expectations

High number of new directors

Full year 2021 earnings: Revenues miss analyst expectations

High number of new directors

Independent Lead Director recently bought CA$92k worth of stock

Independent Lead Director recently bought CA$292k worth of stock

PharmaCielo Ltd. announced that it expects to receive CAD 15 million in funding

Is PharmaCielo (CVE:PCLO) Weighed On By Its Debt Load?

Third quarter 2021 earnings: EPS exceeds analyst expectations while revenues lag behind

Independent Lead Director recently bought CA$1.8m worth of stock

Director Marc Lustig has joined 5th company board

Director Marc Lustig has joined 5th company board

Director Marc Lustig has joined 5th company board

Director Marc Lustig has joined 5th company board

CEO, President & Director Henning von Koss has left the company

Pharmacielo Ltd. Provides Revenue Guidance for the Second Half of 2021

Second quarter 2021 earnings released

Independent Chairman of the Board Simon Langelier has left the company

Chief Financial Officer Scott Laitinen has left the company

First quarter 2021 earnings released: CA$0.047 loss per share (vs CA$0.064 loss in 1Q 2020)

Is PharmaCielo (CVE:PCLO) A Risky Investment?

Independent Director recently bought CA$115k worth of stock

Third quarter 2020 earnings released: CA$0.083 loss per share (vs CA$0.04 loss in 3Q 2019)

PharmaCielo Delivers First Commercial Shipment of THC-Free Broad-Spectrum Distillate

Should PharmaCielo (CVE:PCLO) Be Disappointed With Their 9.8% Profit?

New 90-day high: CA$2.68

PharmaCielo Provides Update on GMP Compliance Process

PharmaCielo Ltd. Announces the Appointment of Caroline Lenardon for Expansion of Retail Investor Relations Capacity

CEO, President & Director recently sold CA$88k worth of stock

New 90-day high: CA$2.18

PharmaCielo Ltd., PharmaCielo Colombia Holdings S.A.S. Enter into Strategic Alliance with AssuredTrans Inc

Revenue and earnings miss expectations

Pharmacielo Ltd. Announces Step Down of David Attard as Board Member, Effective December 1, 2020

PharmaCielo Ltd. Delivers Its First Commercial Shipment of Medicinal Grade CBD Isolate

New 90-day high: CA$0.74

PharmaCielo Ltd. Announces the First Harvest Cycle of Six High-THC Cultivars

PharmaCielo Ltd. announced that it expects to receive CAD 5 million in funding

PharmaCielo Ltd. Appoints Marc Lustig as Lead Director

PharmaCielo Ltd. Expands Portfolio of Cannabis Extracts to Meet Global B2b Medical-Grade Market Demand

New 90-day low: CA$0.54

New 90-day low - CA$0.55

AMMINISTRATORE DELEGATO

Mandato